Special Issue

Optimisation of Therapeutic Targets in Obesity, Inflammation, and Cancers

Message from the Guest Editor

Inflammation is not only the key defence mechanism for the elimination of harmful microorganisms and particles, but also a regulatory process for maintaining internal homeostasis, initiation of differentiation and healing, and anticancer surveillance. Dysbalanced immune responses are linked to obesity and cancer progression. Obesity and other metabolic abnormalities are characterised by a low level of persistent inflammation which can facilitate cancer initiation and support tumorigenesis. Elevated levels of pro-inflammatory markers in elderly patients have also been detected and defined as "inflammageing", which is associated with increased morbidity and mortality. Therefore, priming of patients' immune responses against cancer pathogenesis is a promising strategy in ageing and/or obese populations. Furthermore, the convergence of intracellular mechanisms of cancer progression, inflammation, and metabolic transformation has been detected, suggesting that novel anticancer strategies should target key effectors responsible for regulation of both metabolism and immune system responses.

Guest Editor

Dr. Olga Sukocheva

Lecturer in Health Sciences, College of Nursing and Health Sciences, Flinders University of South Australia, Adelaide 5001, Australia

Deadline for manuscript submissions

closed (28 February 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/78432

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

